Astellas Pharma (4503) Stock Forecast & Price Target

Compare

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4503 Analyst Ratings

Hold

2 Buy

6 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Astellas

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4503 Stock 12 Month Forecast

Average Price Target

¥2,216.67

▲(12.84% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is ¥2,216.67 with a high forecast of ¥2,500.00 and a low forecast of ¥1,600.00. The average price target represents a 12.84% change from the last price of ¥1,964.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1357":"¥1,357","1643":"¥1,643","1929":"¥1,929","2215":"¥2,215","2501":"¥2,501"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥2.50K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2216.6666666666665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥2.22K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥1.60K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1357,1643,1929,2215,2501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2150.5,2177.3846153846152,2204.269230769231,2231.153846153846,2258.0384615384614,2284.923076923077,2311.8076923076924,2338.6923076923076,2365.576923076923,2392.4615384615386,2419.346153846154,2446.230769230769,2473.1153846153848,{"y":2500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2150.5,2155.5897435897436,2160.6794871794873,2165.769230769231,2170.858974358974,2175.948717948718,2181.0384615384614,2186.128205128205,2191.2179487179487,2196.3076923076924,2201.3974358974356,2206.487179487179,2211.576923076923,{"y":2216.6666666666665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2150.5,2108.153846153846,2065.8076923076924,2023.4615384615386,1981.1153846153845,1938.7692307692307,1896.423076923077,1854.076923076923,1811.7307692307693,1769.3846153846152,1727.0384615384614,1684.6923076923076,1642.3461538461538,{"y":1600,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1442.161,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1384.551,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1426.341,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1404.863,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1390.707,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1358.001,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1539.101,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1604.511,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1609.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1613.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1970.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2093,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2150.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥2,500

Average Price Target¥2,217

Lowest Price Target¥1,600

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Nomura

Not Ranked

Nomura

¥2,400→¥2,500

Hold

27.26%

Upside

Downgraded

02/19/26

Nomura downgrades Astellas Pharma (ALPMF) to a Hold

Unknown Analyst

SMBC Nikko

Not Ranked

SMBC Nikko

¥1,700→¥2,000

Hold

1.81%

Upside

Reiterated

02/16/26

SMBC Nikko Sticks to Their Hold Rating for Astellas Pharma (ALPMF)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

¥2,250→¥2,450

Buy

24.71%

Upside

Reiterated

02/05/26

Goldman Sachs Remains a Buy on Astellas Pharma (ALPMF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

¥1,950→¥2,050

Hold

4.35%

Upside

Reiterated

02/05/26

Astellas Pharma (ALPMF) Gets a Hold from Morgan Stanley

Miki Sogi

Bernstein

¥2,000

Hold

1.81%

Upside

Reiterated

02/04/26

Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)

Hidemaru Yamaguchi

Citi

¥2,500

Hold

27.26%

Upside

Reiterated

02/04/26

Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold

Unknown Analyst

Daiwa

Not Ranked

Daiwa

¥1,600

Sell

-18.55%

Downside

Reiterated

01/29/26

Daiwa Sticks to Their Sell Rating for Astellas Pharma (ALPMF)

Unknown Analyst

UBS

Not Ranked

UBS

¥2,350

Hold

19.62%

Upside

Reiterated

01/27/26

UBS Sticks to Their Hold Rating for Astellas Pharma (ALPMF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

¥2,500

Buy

27.26%

Upside

Reiterated

01/26/26

Macquarie Sticks to Their Buy Rating for Astellas Pharma (ALPMF)

Seiji Wakao

J.P. Morgan

¥1,700→¥1,900

Hold

-3.28%

Downside

Reiterated

09/04/25

J.P. Morgan Sticks to Its Hold Rating for Astellas Pharma (ALPMF)

Stephen Barker

Jefferies

¥1,500

Hold

-23.64%

Downside

Reiterated

04/24/25

Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Nomura

Not Ranked

Nomura

¥2,400→¥2,500

Hold

27.26%

Upside

Downgraded

02/19/26

Nomura downgrades Astellas Pharma (ALPMF) to a Hold

Unknown Analyst

SMBC Nikko

Not Ranked

SMBC Nikko

¥1,700→¥2,000

Hold

1.81%

Upside

Reiterated

02/16/26

SMBC Nikko Sticks to Their Hold Rating for Astellas Pharma (ALPMF)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

¥2,250→¥2,450

Buy

24.71%

Upside

Reiterated

02/05/26

Goldman Sachs Remains a Buy on Astellas Pharma (ALPMF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

¥1,950→¥2,050

Hold

4.35%

Upside

Reiterated

02/05/26

Astellas Pharma (ALPMF) Gets a Hold from Morgan Stanley

Miki Sogi

Bernstein

¥2,000

Hold

1.81%

Upside

Reiterated

02/04/26

Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)

Hidemaru Yamaguchi

Citi

¥2,500

Hold

27.26%

Upside

Reiterated

02/04/26

Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold

Unknown Analyst

Daiwa

Not Ranked

Daiwa

¥1,600

Sell

-18.55%

Downside

Reiterated

01/29/26

Daiwa Sticks to Their Sell Rating for Astellas Pharma (ALPMF)

Unknown Analyst

UBS

Not Ranked

UBS

¥2,350

Hold

19.62%

Upside

Reiterated

01/27/26

UBS Sticks to Their Hold Rating for Astellas Pharma (ALPMF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

¥2,500

Buy

27.26%

Upside

Reiterated

01/26/26

Macquarie Sticks to Their Buy Rating for Astellas Pharma (ALPMF)

Seiji Wakao

J.P. Morgan

¥1,700→¥1,900

Hold

-3.28%

Downside

Reiterated

09/04/25

J.P. Morgan Sticks to Its Hold Rating for Astellas Pharma (ALPMF)

Stephen Barker

Jefferies

¥1,500

Hold

-23.64%

Downside

Reiterated

04/24/25

Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astellas Pharma

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+34.50%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +34.50% per trade.

1 Year

xAi Drug Manufacturers - GeneralTipRanks - xAI

Success Rate

1/1 ratings generated profit

Average Return

+34.50%

reiterated a buy rating 18 days ago

Copying xAi Drug Manufacturers - General's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.50% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+34.50%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4503 Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4503 has received 49 Buy Ratings, 21 Hold Ratings, and 1 Sell Ratings. 4503 average Analyst price target in the past 3 months is 2,216.67.

Each month's total comprises the sum of three months' worth of ratings.

4503 Financial Forecast

4503 Earnings Forecast

Next quarter’s earnings estimate for 4503 is ¥13.80 with a range of ¥0.43 to ¥34.40. The previous quarter’s EPS was ¥56.04. 4503 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 4503 has Performed in-line its overall industry.

4503 Sales Forecast

Next quarter’s sales forecast for 4503 is ¥504.71B with a range of ¥471.89B to ¥528.70B. The previous quarter’s sales results were ¥571.21B. 4503 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 4503 has Performed in-line its overall industry.

4503 Stock Forecast FAQ

What is JP:4503’s average 12-month price target, according to analysts?

Based on analyst ratings, Astellas Pharma Inc’s 12-month average price target is 2,216.67.

What is JP:4503’s upside potential, based on the analysts’ average price target?

Astellas Pharma Inc has 12.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Astellas Pharma Inc a Buy, Sell or Hold?

Astellas Pharma Inc has a consensus rating of Hold, which is based on 2 buy ratings, 6 hold ratings and 1 sell ratings.

What is Astellas Pharma Inc’s share price target?

The average share price target for Astellas Pharma Inc is 2,216.67. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥2,500.00 ,and the lowest forecast is ¥1,600.00. The average share price target represents 12.84% Increase from the current price of ¥1,964.5.

What do analysts say about Astellas Pharma Inc?

Astellas Pharma Inc’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Astellas Pharma Inc?

To buy shares of JP:4503, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Astellas Pharma (4503) Stock Forecast & Price Target

4503 Analyst Ratings

4503 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Astellas Pharma

4503 Analyst Recommendation Trends

4503 Financial Forecast

4503 Earnings Forecast

4503 Sales Forecast

4503 Stock Forecast FAQ

Detailed List of Analyst Forecasts